☰

Chuka J. Anude, Ph.D. - Publications

Affiliations: 
2011 Johns Hopkins University, Baltimore, MD 
Area:
Epidemiology, Public Health, Medicine and Surgery
Tree Info Similar researchers PubMed Report error

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, ... ... Anude C, et al. Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial. The Journal of Infectious Diseases. PMID 28199679 DOI: 10.1093/Infdis/Jix086  0.49
2015 Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer SM, Sobieszczyk ME. Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. Clinical Trials (London, England). 12: 394-402. PMID 25851992 DOI: 10.1177/1740774515579165  0.583
2014 Garner SA, Anude CJ, Adams E, Dawson L. Ethical considerations in HIV prevention and vaccine research in resource-limited settings. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 77-83. PMID 25117930 DOI: 10.1097/Qai.0000000000000248  0.367
2013 Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. The New England Journal of Medicine. 369: 2083-92. PMID 24099601 DOI: 10.1056/Nejmoa1310566  0.47
2013 Anude CJ, Eze E, Onyegbutulem HC, Charurat M, Etiebet MA, Ajayi S, Dakum P, Akinwande O, Beyrer C, Abimiku A, Blattner W. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria Bmc Infectious Diseases. 13. PMID 23452915 DOI: 10.1186/1471-2334-13-113  0.446
2012 Anude CJ, Eze E, Onyegbutulem HC, Charurat M, Etiebet M, Ajayi S, Dakum P, Akinwande O, Beyrer C, Abimiku A, Blattner W. AF6 The HACART Study: Predictors of Immuno-Virologic Outcomes and Immuno-Virologic Discordance Among Adults on HIV Antiretroviral Therapy in Nigeria Journal of Acquired Immune Deficiency Syndromes. 59: 30. DOI: 10.1097/01.Qai.0000413826.88167.93  0.432
Show low-probability matches.